Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 Sep;147(3):617–626.

Smooth muscle cells of the coronary arterial tunica media express tumor necrosis factor-alpha and proliferate during acute rejection of rabbit cardiac allografts.

H Tanaka 1, S J Swanson 1, G Sukhova 1, F J Schoen 1, P Libby 1
PMCID: PMC1870969  PMID: 7677176

Abstract

Graft coronary arteriosclerosis (GCA) frequently limits the long-term success of cardiac transplantation. The pathogenic mechanisms of and stimuli that provoke GCA remain uncertain. Whatever the initiating factors, deranged control of smooth muscle cells (SMC) proliferation likely contributes to the intimal hyperplasia that produces obstructive lesions. To identify mediators that may contribute to ongoing modulation of SMC functions during acute rejection and to explore the mechanisms of the pathogenesis of graft coronary arteriosclerosis, we studied the kinetics of proliferation and the expression of tumor necrosis factor-alpha (TNF-alpha), a proinflammatory and SMC growth-promoting cytokine, in coronary arterial SMCs in rabbit hearts transplanted heterotopically without immunosuppression. Hearts were harvested at 2 (n = 5), 5 (n = 5), and 8.2 +/- 0.4 (mean +/- SD, n = 5) days after transplantation, just before graft failure as judged clinically. SMC proliferation was assessed by continuous bromodeoxyuridine labeling (BrdU 10 mg/kg/d. s.q.). Whole heart cross sections were stained immunohistochemically with monoclonal antibodies that recognize TNF-alpha, BrdU, and SMCs (muscle alpha-actin). Major epicardial coronary arteries (five to nine profiles in each animal) were evaluated. Histological rejection grades by the International Society for Heart and Lung Transplantation scale at 2, 5, and 10 days were 1.6 +/- 0.9, 2.8 +/- 1.1, and 4.0 +/- 0.0, respectively. Medial SMCs in normal hearts and 2 days after transplant expressed little or no TNF-alpha and displayed negligible BrdU incorporation. At 5 days after transplantation, some medial SMCs stained for TNF-alpha and had a low BrdU labeling index (0.5 +/- 0.8%). At 8.2 days after transplant, almost all medial SMCs expressed TNF-alpha intensely and had a high labeling index (29.8 +/- 8.0%). These results demonstrate that acute rejection activates medial SMCs in coronary arteries to express TNF-alpha and that SMC-derived TNF-alpha may contribute to medial SMC proliferation in coronary arteries during acute rejection. This finding of early medial SMC replication suggests a novel and heretofore unsuspected mechanism of intimal expansion consequent to the allogeneic state. These results furnish additional insight into the possible mechanisms that link acute rejection with graft coronary arteriosclerosis. Furthermore, the close association of TNF-alpha expression with SMC replication provides not only a novel marker of SMC activation but also a potential new therapeutic target for the prevention of graft coronary disease.

Full text

PDF
617

Images in this article

621Figure 1
on p.621
622Figure 2
on p.622
623Figure 3
on p.623
624Figure 4
on p.624

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alonso D. R., Starek P. K., Minick C. R. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol. 1977 May;87(2):415–442. [PMC free article] [PubMed] [Google Scholar]
  2. Barath P., Fishbein M. C., Cao J., Berenson J., Helfant R. H., Forrester J. S. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol. 1990 Feb 1;65(5):297–302. doi: 10.1016/0002-9149(90)90291-8. [DOI] [PubMed] [Google Scholar]
  3. Barbir M., Kushwaha S., Hunt B., Macken A., Thompson G. R., Mitchell A., Robinson D., Yacoub M. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet. 1992 Dec 19;340(8834-8835):1500–1502. doi: 10.1016/0140-6736(92)92756-6. [DOI] [PubMed] [Google Scholar]
  4. Bevilacqua M. P., Pober J. S., Majeau G. R., Fiers W., Cotran R. S., Gimbrone M. A., Jr Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4533–4537. doi: 10.1073/pnas.83.12.4533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Billingham M. E. Cardiac transplant atherosclerosis. Transplant Proc. 1987 Aug;19(4 Suppl 5):19–25. [PubMed] [Google Scholar]
  6. Billingham M. E., Cary N. R., Hammond M. E., Kemnitz J., Marboe C., McCallister H. A., Snovar D. C., Winters G. L., Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant. 1990 Nov-Dec;9(6):587–593. [PubMed] [Google Scholar]
  7. Cerilli J., Brasile L., Galouzis T., Lempert N., Clarke J. The vascular endothelial cell antigen system. Transplantation. 1985 Mar;39(3):286–289. doi: 10.1097/00007890-198503000-00016. [DOI] [PubMed] [Google Scholar]
  8. Clausell N., Molossi S., Sett S., Rabinovitch M. In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation. 1994 Jun;89(6):2768–2779. doi: 10.1161/01.cir.89.6.2768. [DOI] [PubMed] [Google Scholar]
  9. Clowes A. W., Clowes M. M., Fingerle J., Reidy M. A. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol. 1989;14 (Suppl 6):S12–S15. [PubMed] [Google Scholar]
  10. Dunn M. J., Crisp S. J., Rose M. L., Taylor P. M., Yacoub M. H. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 1992 Jun 27;339(8809):1566–1570. doi: 10.1016/0140-6736(92)91832-s. [DOI] [PubMed] [Google Scholar]
  11. Eich D., Thompson J. A., Ko D. J., Hastillo A., Lower R., Katz S., Katz M., Hess M. L. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant. 1991 Jan-Feb;10(1 Pt 1):45–49. [PubMed] [Google Scholar]
  12. Gao S. Z., Schroeder J. S., Hunt S. A., Valantine H. A., Hill I. R., Stinson E. B. Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. J Heart Lung Transplant. 1993 Nov-Dec;12(6 Pt 1):1029–1035. [PubMed] [Google Scholar]
  13. Hajjar K. A., Hajjar D. P., Silverstein R. L., Nachman R. L. Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med. 1987 Jul 1;166(1):235–245. doi: 10.1084/jem.166.1.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hanke H., Strohschneider T., Oberhoff M., Betz E., Karsch K. R. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res. 1990 Sep;67(3):651–659. doi: 10.1161/01.res.67.3.651. [DOI] [PubMed] [Google Scholar]
  15. Hosenpud J. D., Shipley G. D., Wagner C. R. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant. 1992 Jan-Feb;11(1 Pt 1):9–23. [PubMed] [Google Scholar]
  16. Libby P., Ordovas J. M., Auger K. R., Robbins A. H., Birinyi L. K., Dinarello C. A. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986 Aug;124(2):179–185. [PMC free article] [PubMed] [Google Scholar]
  17. Libby P., Salomon R. N., Payne D. D., Schoen F. J., Pober J. S. Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis. Transplant Proc. 1989 Aug;21(4):3677–3684. [PubMed] [Google Scholar]
  18. Loppnow H., Libby P. Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res. 1989 Fall;8(3):293–299. [PubMed] [Google Scholar]
  19. Masetti P., DiSesa V. J., Schoen F. J., Sun S. C., Byrne J. G., Appleyard R. F., Laurence R., Cohn L. H. Ischemic injury before heart transplantation does not cause coronary arteriopathy in experimental isografts. J Heart Lung Transplant. 1991 Jul-Aug;10(4):597–599. [PubMed] [Google Scholar]
  20. Miller L. W. Transplant coronary artery disease. J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S1–S4. [PubMed] [Google Scholar]
  21. Nakagawa T., Sukhova G. K., Rabkin E., Winters G. L., Schoen F. J., Libby P. Acute rejection accelerates graft coronary disease in transplanted rabbit hearts. Circulation. 1995 Aug 15;92(4):987–993. doi: 10.1161/01.cir.92.4.987. [DOI] [PubMed] [Google Scholar]
  22. Nawroth P. P., Bank I., Handley D., Cassimeris J., Chess L., Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1363–1375. doi: 10.1084/jem.163.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Noronha I. L., Eberlein-Gonska M., Hartley B., Stephens S., Cameron J. S., Waldherr R. In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 receptors in renal allograft biopsies. Transplantation. 1992 Dec;54(6):1017–1024. doi: 10.1097/00007890-199212000-00015. [DOI] [PubMed] [Google Scholar]
  24. Palmer H., Libby P. Interferon-beta. A potential autocrine regulator of human vascular smooth muscle cell growth. Lab Invest. 1992 Jun;66(6):715–721. [PubMed] [Google Scholar]
  25. Pober J. S., Cotran R. S. Cytokines and endothelial cell biology. Physiol Rev. 1990 Apr;70(2):427–451. doi: 10.1152/physrev.1990.70.2.427. [DOI] [PubMed] [Google Scholar]
  26. Rose E. A., Pepino P., Barr M. L., Smith C. R., Ratner A. J., Ho E., Berger C. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S120–S123. [PubMed] [Google Scholar]
  27. Salomon R. N., Hughes C. C., Schoen F. J., Payne D. D., Pober J. S., Libby P. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991 Apr;138(4):791–798. [PMC free article] [PubMed] [Google Scholar]
  28. Sawada H., Kan M., McKeehan W. L. Opposite effects of monokines (interleukin-1 and tumor necrosis factor) on proliferation and heparin-binding (fibroblast) growth factor binding to human aortic endothelial and smooth muscle cells. In Vitro Cell Dev Biol. 1990 Feb;26(2):213–216. doi: 10.1007/BF02624115. [DOI] [PubMed] [Google Scholar]
  29. Stovin P. G., Sharples L. D., Schofield P. M., Cary N. R., Mullins P. A., English T. A., Wallwork J., Large S. R. Lack of association between endomyocardial evidence of rejection in the first six months and the later development of transplant-related coronary artery disease. J Heart Lung Transplant. 1993 Jan-Feb;12(1 Pt 1):110–116. [PubMed] [Google Scholar]
  30. Tanaka H., Sukhova G. K., Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb. 1994 May;14(5):734–745. doi: 10.1161/01.atv.14.5.734. [DOI] [PubMed] [Google Scholar]
  31. Tanaka H., Sukhova G. K., Swanson S. J., Cybulsky M. I., Schoen F. J., Libby P. Endothelial and smooth muscle cells express leukocyte adhesion molecules heterogeneously during acute rejection of rabbit cardiac allografts. Am J Pathol. 1994 May;144(5):938–951. [PMC free article] [PubMed] [Google Scholar]
  32. Uretsky B. F., Murali S., Reddy P. S., Rabin B., Lee A., Griffith B. P., Hardesty R. L., Trento A., Bahnson H. T. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987 Oct;76(4):827–834. doi: 10.1161/01.cir.76.4.827. [DOI] [PubMed] [Google Scholar]
  33. Vilcek J., Palombella V. J., Henriksen-DeStefano D., Swenson C., Feinman R., Hirai M., Tsujimoto M. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med. 1986 Mar 1;163(3):632–643. doi: 10.1084/jem.163.3.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Warner S. J., Libby P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol. 1989 Jan 1;142(1):100–109. [PubMed] [Google Scholar]
  35. Wiesner R. H., Ludwig J., van Hoek B., Krom R. A. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology. 1991 Oct;14(4 Pt 1):721–729. doi: 10.1016/0270-9139(91)90064-3. [DOI] [PubMed] [Google Scholar]
  36. Yoshizumi M., Kourembanas S., Temizer D. H., Cambria R. P., Quertermous T., Lee M. E. Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells. J Biol Chem. 1992 May 15;267(14):9467–9469. [PubMed] [Google Scholar]
  37. Zerbe T., Uretsky B., Kormos R., Armitage J., Wolyn T., Griffith B., Hardesty R., Duquesnoy R. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S104–S110. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES